Chain Drug Review - Xalatan combination considered
February 28, 2000 -- Pharmacia & Upjohn Inc. has submitted a new drug application for a combination ophthalmic product for treating glaucoma. The product, a fixed...
Review of Optometry - Alphagan, Xalatan Among Drugs Costing Seniors More.
July 15, 2001 -- The 50 most heavily prescribed drugs for seniors rose in price, on average, at more than twice the rate of inflation over the past year, reports a...
Biotech Business - STUDY SHOWS LUMIGAN MORE EFFECTIVE THAN XALATAN.
May 1, 2001 -- Allergan, Inc. (NYSE:AGN) has released a three-month comparison study of LUMIGAN(TM) (bimatoprost ophthalmic solution) 0.03%, and Xalatan(R)...
Market Wire - NicOx provides update on PF-03187207 and the ongoing research collaboration with Pfizer
August 25, 2008 -- August 25, 2008. Sophia Antipolis,France. www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of adose-ranging phase 2 study...
Business Wire - LUMIGAN Outcome Favorable in Comparison Study with Xalatan; LUMIGAN - Xalatan Comparison Presented at International Glaucoma Symposium
March 24, 2001 -- Business Editors & Health/Medical Writers PRAGUE, Czech Republic--(BW HealthWire)--March 24, 2001 Allergan, Inc. (NYSE:AGN) released a...
Business Wire - Lux Biosciences Names Paul Chaney, Former President Eyetech and EVP OSI Pharmaceuticals, to Board of Directors
August 12, 2008 -- JERSEY CITY, N.J. -- Lux Biosciences today announced the appointment of Paul G. Chaney to the company's board of directors. Mr. Chaney is the former...
Market Wire - NicOx announces U.S. phase 2a results for PF-03187207 and gives an update on continuing NO-prostaglandin program
May 6, 2008 -- www.nicox.com NicOx S.A. (Euronext Paris: COX) today announced the results of a U.S.phase 2 study, conducted by its partner Pfizer Inc, which...
Chain Drug Review - Lipitor on formulary
June 25, 2007 -- Pfizer Inc. says Lipitor is now included on the national preferred formulary of Express Scripts Inc. Pfizer's Xalatan (glaucoma) and Celebrex...
Medical Marketing and Media - Xalatan brochure called
February 1, 1999 -- > The DDMAC sent a second letter in November to Pharmacia & Upjohn, with objections this time to a brochure for its Xalatan sterile ophthalmic...
Optometric Management - THERAPEUTIC Notes
July 1, 2006 -- * Transitions has created a new database that will allow ECPs to access information on drugs that may cause ocular side effects. The "Ocular Side...
